Related Experiment Video
Updated: May 9, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Immunogenicity of inactivated hepatitis A vaccine in children
1Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Insights
The inactivated hepatitis A vaccine is safe and effective in children. It demonstrated high seroconversion rates and no significant side effects, making it a viable option for hepatitis A prevention.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Inactivated hepatitis A vaccine availability is increasing globally.
- Hepatitis A remains a public health concern, necessitating effective prevention strategies.
Purpose of the Study:
- To assess the immunogenicity and safety of an inactivated hepatitis A vaccine in children.
- To establish optimal vaccination schedules for pediatric populations.
Main Methods:
- A study involving 99 susceptible schoolchildren aged 4-15 years.
- Administration of 360 ELISA units of inactivated hepatitis A vaccine at 0, 1, and 6 months.
- Monitoring of antibody titers and adverse events post-vaccination.
Main Results:
- High seroconversion rates: 97% after the first dose, 100% after the second and booster doses.
- Geometric mean titers increased significantly after each dose, reaching 4133 mIU/mL after the booster.
- No significant adverse events were reported, indicating a favorable safety profile.
Conclusions:
- The inactivated hepatitis A vaccine is both safe and immunogenic in healthy children.
- The vaccine establishes protective antibody levels, supporting its use in pediatric hepatitis A prevention programs.
Background:
Inactivated hepatitis A vaccine is now becoming available in many countries.
Methods:
To evaluate the immunogenicity and safety of inactivated hepatitis A vaccine in healthy children, 99 susceptible schoolchildren from 4 to 15 years of age received 360 enzyme-linked immunosorbent assay units of the inactivated hepatitis A vaccine at months 0, 1, and 6.
Results:
Antibody to hepatitis A virus seroconversion (> or = 20 mIU/mL) was 97% (96/99) in vaccinees after the first dose and 100% after the second (99/99) and booster (96/96) doses. The geometric mean titers of antibody to hepatitis A virus were 167, 465, and 4133 mIU/mL after each dose of vaccine, respectively. There were no significant side effects during the vaccination. Levels of antibody to hepatitis A virus were also tested in 9 susceptible children at day 7 and months 1 and 4 after the intramuscular injection of 2 mL of immune serum globulin. All children had measurable titers of antibody to hepatitis A virus 1 week after receiving immune serum globulin by sensitive enzyme immunoassay, but measurable titers had disappeared 1-4 months later.
Conclusions:
The inactivated hepatitis A vaccine is safe and immunogenic in healthy children.
More Related Videos
Related Concept Videos
Vaccinations
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccines

